Your browser doesn't support javascript.
loading
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Jin, Jie; Zhang, Lei; Qin, Albert; Wu, Daoxiang; Shao, Zonghong; Bai, Jie; Chen, Suning; Duan, Minghui; Zhou, Hu; Xu, Na; Zhang, Sujiang; Zuo, Xuelan; Du, Xin; Wang, Li; Li, Pei; Zhang, Xuhan; Li, Yaning; Zhang, Jingjing; Wang, Wei; Shen, Weihong; Zagrijtschuk, Oleh; Urbanski, Raymond; Sato, Toshiaki; Xiao, Zhijian.
Afiliación
  • Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. jiej0503@zju.edu.cn.
  • Zhang L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China. zhanglei1@ihcams.ac.cn.
  • Qin A; Medical Research & Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan, Republic of China. albert_qin@pharmaessentia.com.
  • Wu D; PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
  • Shao Z; The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Bai J; The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Chen S; The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Duan M; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhou H; Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China.
  • Xu N; Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China.
  • Zhang S; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Zuo X; Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China.
  • Du X; Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
  • Wang L; The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Li P; Huashan Hospital of Fudan University, Shanghai, China.
  • Zhang X; Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
  • Li Y; PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
  • Zhang J; PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
  • Wang W; PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
  • Shen W; PharmaEssentia Biotech (Beijing) Limited, Beijing, China.
  • Zagrijtschuk O; PharmaEssentia USA Corporation, Burlington, MA, USA.
  • Urbanski R; PharmaEssentia USA Corporation, Burlington, MA, USA.
  • Sato T; PharmaEssentia Japan K. K, Motoakasaka, Minato-Ku, Tokyo, Japan.
  • Xiao Z; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Exp Hematol Oncol ; 12(1): 55, 2023 Jun 21.
Article en En | MEDLINE | ID: mdl-37344895
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Exp Hematol Oncol Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Exp Hematol Oncol Año: 2023 Tipo del documento: Article País de afiliación: China